Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer
AssigneeThe United States of America as represented by the Department of Veterans Affairs
InventorKatherine Meyer Siegler
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for detecting, diagnosing or prognosticating prostate cancer by measuring the levels of macrophage migration inhibitory factor (MIF) in the serum of an individual. The assay for MIF can be an immunoassay, such as ELISA, or a nucleic assay, such as Nouthern blot. Genetic changes within MIF gene can predict patients that express high levels of MIF.
Claims93
A method for detecting, diagnosing or prognosticating prostate cancer in an individual comprising the step of determining levels of macrophage migration inhibitory factor (MIF) in the serum of the individual.
A method for monitoring the treatment of an individual with prostate cancer comprising the steps of
- administering a pharmaceutical composition for treating prostate cancer to the individual;
- and
- determining levels of macrophage migration inhibitory factor (MIF) in the serum of the individual.
A method for screening for an agent capable of modulating the onset or progression of prostate cancer comprising
- exposing an individual to the agent;
- and
- determining levels of macrophage migration inhibitory factor (MIF) in the serum of the individual.
A method for monitoring the progression of prostate cancer comprising determining levels of macrophage migration inhibitory factor (MIF) in the serum of the individual.
Dependencies are inferred from the claim text.